Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo. The US regulator says Retevmo ...

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Heading Lilly’s newly-acquired cancer assets is LOXO-292, an oral RET inhibitor that Loxo and Lilly say is a first-in-class drug that could reach the market next year. It has a breakthrough ...

kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and ...

5). The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

Inhibition of RET by siRNA-mediated knockdown or treatment with the tyrosine kinase inhibitor selpercatinib impaired the growth of CDK4/6i- and fulvestrant-resistant cell lines and patient-derived ...